IP Verse

Tropism-Modified Recombinant Viral Particles And Uses Thereof For The Targeted Introduction Of Genetic Material Into Human Cells

Patent No. EP3645553 (titled "Tropism-Modified Recombinant Viral Particles And Uses Thereof For The Targeted Introduction Of Genetic Material Into Human Cells") was filed by Regeneron Pharmaceuticals on Jun 27, 2018. The application was issued on Mar 15, 2023.

Patent Summary

Recombinant viral capsid that optimizes the problems inherent in previous retargeting strategies by utilizing a first member and a second cognate member of a specific binding pair, which first member and second cognate member specifically interact to form an isopeptide bond. The first member, when displayed on a capsid protein, acts as a scaffold for any targeting ligand fused to the second cognate member, but upon binding of the first member and second cognate member, an isopeptide bond forms, and the recombinant viral particle acts as a one-component targeting vector.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANDec 15, 2023DEHNS
STRAWMANDec 15, 2023LONGLAND
JG OPPOSITIONSDec 14, 2023WILDING

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3645553

REGENERON PHARMACEUTICALS
Application Number
EP18749636A
Filing Date
Jun 27, 2018
Status
Granted And Under Opposition
Feb 10, 2023
Publication Date
Mar 15, 2023
External Links
Slate, Register , Google Patents